Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $40.27 which represents a slight increase of $0.68 or 1.72% from the prior close of $39.59. The stock opened at $39.59 and touched a low ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have ...

Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...

A pediatric vaccine for respiratory syncytial virus (RSV) is proving to be elusive, according to news from the U.S. Food and ...

The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

Moderna Inc. closed $130.88 short of its 52-week high ($170.47), which the company reached on May 24th.

Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on ...

Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell in ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $39.39 which represents a decrease of $-0.17 or -0.43% from the prior close of $39.56. The stock opened at $39.2 and touched a low of $39.12 ...

The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the ...